Sage Therapeutics' (SAGE) CORAL Phase 3 Study Likely to Meet Primary Endpoint, But Not Enough to Drive Stock Higher - Needham & Company
Go back to Sage Therapeutics' (SAGE) CORAL Phase 3 Study Likely to Meet Primary Endpoint, But Not Enough to Drive Stock Higher - Needham & Company| Sagebrush Gold Ltd. (NASDAQ: SAGE) | Delayed: 14.00 +1.05 (8.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.95 | 52 Week High | $62.64 | |||
| Open | $13.85 | 52 Week Low | $26.28 | |||
| Day High | $14.52 | P/E | N/A | |||
| Day Low | $13.45 | EPS | $-0.94 | |||
| Volume | 2,521,842 | |||||
